Table 1.
Baseline Characteristics of Study Population (n=80). Continuous variables are expressed as mean±standard deviation.
| Patient Characteristic | |
|---|---|
| Mean age (years) | 63.1 |
| Female (%) | 55 (68.8) |
| White (%) | 55 (68.8) |
| Body Mass Index (kilogram/meter2) Comorbid conditions | 30±7.0 |
| • Left heart disease | 17 (21.3) |
| • Diabetes mellitus | 18 (22.5) |
| • Hypertension | 36 (45.0) |
| • Depression | 4 (5.0) |
| • Obesity | 25 (31.3) |
| • Obstructive sleep apnea | 20 (25.0) |
| • Renal disease | 11 (13.8) |
| • Interstitial lung disease/ pulmonary fibrosis | 20 (25.0) |
| • Obstructive lung disease | 23 (28.8) |
| • Sarcoidosis | 2 (2.5) |
| • Venous thromboembolic disease | 11 (13.8) |
| • Non-skin cancer | 9 (11.3) |
| PH World Health Organization Classification | |
| • Group 1 | 41 (51.9) |
| ∘ Idiopathic | 16 (40.0) |
| ∘ Familial | 1 (2.5) |
| ∘ Drug/toxin-induced | 2 (5.0) |
| ∘ Connective tissue disease | 15 (37.5) |
| ∘ Human Immunodeficiency Virus | 2 (5.0) |
| ∘ Portopulmonary hypertension | 1 (2.5) |
| ∘ Congenital heart disease | 3 (7.5) |
| • Group 2 | 3 (3.8) |
| • Group 3 | 25 (31.6) |
| ∘ Obstructive disease | 13 (52.0) |
| ∘ Interstitial lung disease/fibrosis | 6 (24.0) |
| ∘ Mixed pattern | 6 (24.0) |
| • Group 4 | 9 (11.4) |
| • Group 5 | 1 (1.3) |
| Concomitant pulmonary hypertension medications | |
| • Endothelin receptor antagonist | 46 (57.5) |
| • Phosphodiesterase-5 inhibitor | 53 (66.3) |
| • Oxygen (continuous) | 46 (57.5) |
| Biomarkers | |
| World Health Organization Functional Class III/IV | 62 (77.5) |
| Bo Borg Dyspnea Index Score core | 3.6±2.2 |
| Mean 6-minute walk distance (meters) | 302±135 |
| NT-proBNP (ng/L) (reference range < 125) | 1923±3086 |